Wyeth Pharmaceuticals has agreed to pay $200 million to resolve claims that their Premarin hormone replacement therapy drugs were misrepresented.
The settlement benefits California consumers who bought Premarin, Prempro, and/or Premphase in California between January 1995 and January 2003, and who are not claiming any personal injury in connection to the drugs.
Plaintiffs in the hormone replacement therapy class action lawsuit claimed that Wyeth Pharmaceuticals misrepresented their Premarin, Prempro and Premphase products, along with the associated risks.
Between January 1995 and January 2003, the company allegedly claimed that the drugs lowered cardiovascular, Alzheimer’s and dementia risks while not increasing breast cancer risks. These claims were reportedly false.
The Premarin class action lawsuit secured Class certification in 2011, although several back and forth motions were filed in the following years. These motions included bids for summary judgment, appeals and more.
In February, the court set a trial date of May 5 for the Premarin class action lawsuit. However, in early March, the plaintiffs filed a document in court detailing the settlement agreement reached between Premarin plaintiffs and Wyeth Pharmaceuticals.
Wyeth Pharmaceuticals has not admitted any wrongdoing by settling the Premarin hormone replacement therapy class action lawsuit. Instead, the $200 million settlement provides a resolution to the claims which allows all parties to avoid the future cost of litigation.
If the Premarin class action settlement is granted final approval by the court, the deal will allow the parties to avoid a trial and its associated uncertainties.
There are two forms of compensation available under the Premarin class action settlement.
The first award option includes a one time payment of $458.64. This amount compensates consumers for 24 months of out-of-pocket costs for Premarin, Prempro, and/or Premphase in California between January 1995 and January 2003.
Class Members who recover this option are not required to provide proof of purchase and instead will need to provide general information about the prescriptions and purchases.
The second award option is larger but requires more proof. Under this option, Class Members can collect a payment compensating them for the number of months they paid out-of-pocket costs for Premarin, Prempro and Premphase between January 1995 and January 2003.
Payments include $19.11 per every month that a Class Member paid these costs. Up to 97 months can be claimed for a maximum payment of $1,853.67, if Class Members provide proof of purchase for monthly out-of-pocket expenses.
In order to benefit from the settlement, Class Members must file a valid claim form by Sept. 1, 2020. The deadline for exclusion and objection is July 14, 2020. The final approval hearing for the settlement is scheduled for Aug. 14, 2020.
California consumers who bought Premarin, Prempro, and/or Premphase in California between January 1995 and January 2003 and who are not claiming any personal injury in connection to the drugs.
Up to $1,853.67.
There are two options of compensation available:
- A one time payment of $458.64. This amount is equal to the 24 months of average out-of-pocket costs of Premarin, Prempro and Premphase between January 1995 and January 2003.
- Reimbursement for up to 97 months of the drugs for a total of up to $1,853.67. Payments include $19.11 per every month that a Class Member paid out-of-pocket for Premarin, Prempro and Premphase between January 1995 and January 2003.
Proof of Purchase
Compensation Option 1 requires only information about prescriptions and purchases. Compensation Option 2 requires proof of monthly out-of-pocket expenses.
NOTE: If you do not qualify for this settlement do NOT file a claim.
Remember: you are submitting your claim under penalty of perjury. You are also harming other eligible Class Members by submitting a fraudulent claim. If you’re unsure if you qualify, please read the FAQ section of the Settlement Administrator’s website to ensure you meet all standards (Top Class Actions is not a Settlement Administrator). If you don’t qualify for this settlement, check out our database of other open class action settlements you may be eligible for.
Claim Form Deadline
Krueger v. Wyeth Inc., et al., Case No. 3:03-cv-02496-JAH-MDD, in the U.S. District Court for the Southern District of California
California Hormone Replacement Therapy Class – 6900
c/o Rust Consulting
PO Box 540
Minneapolis MN 55440-0540
RUSHALL & MCGEEVER APLC
GARY HOLT & ASSOCAITES PA
BEASLEY ALLEN CROW METHVIN PORTIS & MILES PC
WILKINSON WALSH LLP
DLA PIPER LLP
WILLIAMS & CONNOLLY LLP
Read More Lawsuit & Settlement News:
Top Class Actions is a Proud Member of the American Bar Association
LEGAL INFORMATION IS NOT LEGAL ADVICE
©2008 – 2020 Top Class Actions® LLC
Various Trademarks held by their respective owners
This website is not intended for viewing or usage by European Union citizens.
Please note: Top Class Actions is not a settlement administrator or law firm. Top Class Actions is a legal news source that reports on class action lawsuits, class action settlements, drug injury lawsuits and product liability lawsuits. Top Class Actions does not process claims and we cannot advise you on the status of any class action settlement claim. You must contact the settlement administrator or your attorney for any updates regarding your claim status, claim form or questions about when payments are expected to be mailed out.